Resumen
The present invention relates to a lipid system that not only improves the stability and oral bioavailability of various biologically active compounds during digestion in a safe and efficient manner,but also enhances the effects of the compounds in many instances. The present invention also relates to a formulation or composition comprising a biologically active compound-carrying lipid system foruse as an immunotherapeutic potentiators or adjuvant for patients with cancer or immunological disorders.
Reivindicaciones
1. A composition comprising a supercritical rosemary extract (SRE) and a lipid system in turn comprising ratfish liver oil (RLO) or the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil (RLO). 2. The composition according to claim 1, where said composition is characterized in that it comprises ratfish liver oil (RLO) and SRE. 3. The composition according to claim 2, where said composition further comprises monoglycerides, preferably between 2 and 30% w/w of monoglycerides. 4. The composition according to claim 3, where said monoglycerides are selected from the list consisting of monoolein (MO) and monostearin (MS). 5. The composition according to claim 4, where said monoglyceride is MS. 6. The composition according to claim 5, where said composition consists of +/- 30% of a composition comprising: a. 91.2% w/w of RLO, b. 5.2% w/w of SRE, and c. 3.6% w/w of MS. 7. The composition according to claim 1, where the lipid system is the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil, characterized in that it comprises: a. between 25% and 35% (w/w) of monoglycerides and/or free alkylglycerols; b. between 10% and 25% (w/w) of diacylglycerol ethers (DAGEs); and c. between 40% and 60% (w/w) of monoacylglycerol ethers (MAGEs) and/or diacylglycerols (DAGs), where the proportion of MAGEs with respect to the total amount of MAGEs and DAGs present in the lipid system is at least 50% (w/w). 8. The composition according to claim 1, where the lipid system is the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil, characterized in that it comprises: a. between 25% and 35% (w/w) of monoglycerides and/or free alkylglycerols; b. between 10% and 25% (w/w) of diacylglycerol ethers (DAGEs); c. between 0 and 5% (w/w) of triglycerides; d. between 0 and 3% of glycerin; and e. between 40% and 60% (w/w) of monoacylglycerol ethers (MAGEs) and/or diacylglycerols (DAGs), where the proportion of MAGEs with respect to the total amount of MAGEs and DAGs present in the lipid system is at least 50% (w/w). 9. The composition according to claim 1, where the lipid system is the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil, characterized in that it comprises: a. between 28% and 32% (w/w) of monoglycerides and/or free alkylglycerols; b. between 18% and 22% (w/w) of diacylglycerol ethers (DAGEs); c. between 0 and 2% (w/w) of triglycerides; d. between 1% and 3% of glycerin; and e. between 40% and 50% (w/w) of monoacylglycerol ethers (MAGEs) and/or diacylglycerols (DAGs), where the proportion of MAGEs with respect to the total amount of MAGEs and DAGs present in the lipid system is at least 50% (w/w). 10. The composition according to any of claims 1 to 9 for use as immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders. 11. The composition according to any of claims 1 to 9 for use in the treatment of a patient with an autoimmune-based immunological disorder selected from the list consisting of: rheumatoid arthritis, type I diabetes, psoriasis, celiac disease and multiple sclerosis. 12. The composition according to any of claims 1 to 9 for use in the treatment of a patient with tumor growth, chronic lymphocytic choriomeningitis virus infection, hepatitis (B and C) virus infection, or human immunodeficiency virus infection. 13. The composition according to any of claims 1 to 9 for use in the prevention of kidney damage. 14. Use of the composition according to any of claims 1 to 9 for the elaboration of a pharmaceutically acceptable or food-grade vehicle for functional foods, nutraceutical products, natural extracts or drugs, preferably anticancer drugs. 15. Food composition comprising the composition according to any of claims 1 to 9. 16. Pharmaceutical composition comprising the composition according to any of claims 1 to 9 and optionally pharmaceutically acceptable excipients.
